about
Design and application of multifunctional DNA nanocarriers for therapeutic deliverySolution-state structure of a fully alternately 2'-F/2'-OMe modified 42-nt dimeric siRNA constructHigh-Density Lipoproteins: Nature's Multifunctional NanoparticlesPreclinical and clinical development of siRNA-based therapeuticsTechnologies for controlled, local delivery of siRNAProgress toward in vivo use of siRNAs-IIRNAi screening comes of age: improved techniques and complementary approachesAcoustic Cavitation-Mediated Delivery of Small Interfering Ribonucleic Acids with Phase-Shift Nano-EmulsionsOnline GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis.Applications of mass spectrometry to the study of siRNA.Sequence-non-specific effects of RNA interference triggers and microRNA regulators.Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.Advances in Systemic siRNA DeliveryIs there a role for voltage-gated Na+ channels in the aggressiveness of breast cancer?High-density lipoproteins for the systemic delivery of short interfering RNA.In silico design and enzymatic synthesis of functional RNA nanoparticles.Rational design of immunostimulatory siRNAs.Modular and Chemically Responsive Oligonucleotide "Bonds" in Nanoparticle Superlattices.Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.Dual-targeting siRNAsProstate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles.Probing the inherent stability of siRNA immobilized on nanoparticle constructs.siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract.Efficient HIV-1 inhibition by a 16 nt-long RNA aptamer designed by combining in vitro selection and in silico optimisation strategies.Screening mutant libraries of T7 RNA polymerase for candidates with increased acceptance of 2'-modified nucleotides.Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging.Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes.Treatment with connexin 46 siRNA suppresses the growth of human Y79 retinoblastoma cell xenografts in vivoRNA interference for improving the outcome of islet transplantation.8-Oxoguanosine switches modulate the activity of alkylated siRNAs by controlling steric effects in the major versus minor grooves.RNAi medicine for the brain: progresses and challenges.RNA interference screening for the discovery of oncology targets.Wound healing improvement with PHD-2 silenced fibroblasts in diabetic mice.Electroporation and microinjection successfully deliver single-stranded and duplex DNA into live cells as detected by FRET measurements.Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.Cellular dynamics of RNA modification.Towards Fluorescence In Vivo Hybridization (FIVH) Detection of H. pylori in Gastric Mucosa Using Advanced LNA Probes.gespeR: a statistical model for deconvoluting off-target-confounded RNA interference screensHuman Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo
P2860
Q27007011-E83F2877-0A75-41D2-B654-0BB1AB85D0B3Q27663362-686D36DD-3F4E-4733-A926-17B25E93CF8CQ28077290-D08181D8-C052-4D78-AC3F-75B6C85FD5FBQ28085290-50BF4F3F-5E99-4938-8E00-F001968CA0F9Q28087657-00465D74-8D0C-45A9-A5F7-694C2EC6ED66Q28255877-285C0FDB-4603-4EFB-B665-8B5A3C3DA44FQ28654521-32E4AA4F-7645-4F99-8531-51CEE7FCC0D5Q30378008-BB027E46-58AF-4E1C-A215-593208D46B80Q30831501-B46BFF53-47AF-43F6-9B86-8647F48397A9Q33536680-2735E99F-EB65-4871-B246-9910BA439A34Q33566425-B3019364-9C28-4237-9E47-7922C8F8E796Q33572902-9F10D2DD-1169-4898-920A-116786138176Q33613316-6A5CC4CC-B8CC-46CF-8DC8-565CA89C9364Q33777055-0FD294C0-C5A0-42CB-863A-83E955259D8BQ33786171-D87CF3F0-B900-4108-A3D8-0A0EEA0F0567Q33791733-C568397D-F87C-42D3-AC6D-505D9FBE9E21Q33822185-4F9A983F-694A-4732-A93E-3C9BC83AE992Q33850611-C17ECCA3-CB85-481A-8034-3137345944D8Q33865784-406084D6-FDC2-4C0F-A272-F6CFA8E7604FQ33867488-9959AA65-1086-4D3C-84EA-A81D0515129DQ33893647-C6563348-834B-4443-8FE8-BAD2D7AB07E5Q33902729-96A66B27-BDD0-48A5-89AF-C6602EA6011BQ33919726-1A313656-D6D1-4433-9E40-3A39E9CE7561Q33925270-260AF81C-4B2C-4863-ACFB-FBBC5C0BC478Q34112867-A92D6A33-76AB-4158-8E4E-EB9D2B2D78E2Q34397679-5E945A56-6B8E-4D07-B00D-609F58C60B3AQ34520490-4C4715BC-C670-4A82-AB55-CA7960FB52C1Q34564940-E63694D2-E31A-47F6-9601-264D1A5EEFE4Q34699375-2A972763-B7BE-45FB-8838-8D31AEA89645Q34729434-63A4B892-3B98-4BB2-80A4-71596709076EQ34906848-7E10E6B2-5C3F-4081-8B56-B3CC94BD658EQ34982838-BD7B32DA-FF91-4DD5-813E-25A1221787E8Q34995323-9E288A5E-F0A5-461B-A7E5-1C78B66FD20EQ35078425-1F8CAA84-FED6-4D96-94BF-14F611A58AB4Q35154985-8EF1D29B-48ED-4773-AB27-432C111B8E57Q35230177-C56E7A7A-9F33-4EC1-84BD-58640468125FQ35230650-0E99CA42-A2A2-4241-A335-9A32842BA7FDQ35615550-C30E327A-B864-43C4-8D54-0FA3D046586DQ35800841-CA85CE1C-30BD-415E-82B8-FE62D40540A9Q35813800-28398F6D-EBC5-4B6F-8283-A18E625AC74B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
gotara zanistî
@ku-latn
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Chemical modification of siRNAs for in vivo use.
@en
Chemical modification of siRNAs for in vivo use.
@nl
type
label
Chemical modification of siRNAs for in vivo use.
@en
Chemical modification of siRNAs for in vivo use.
@nl
prefLabel
Chemical modification of siRNAs for in vivo use.
@en
Chemical modification of siRNAs for in vivo use.
@nl
P356
P1433
P1476
Chemical modification of siRNAs for in vivo use
@en
P2093
Mark A Behlke
P304
P356
10.1089/OLI.2008.0164
P577
2008-12-01T00:00:00Z